MGTA News and Press, Magenta Therapeutics Inc. From 02/02/23

Magenta Therapeutics ( NASDAQ: MGTA ) has added 47% in post-market trading after saying it will stop development of its program and conduct a review of strategic alternatives. These alternatives can include an acquisition, merger, or business combination. Over the last yea...

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that it has completed a review of its business, including the status of its programs, resources, and capa...

Magenta Therapeutics ( NASDAQ: MGTA ) lost ~11% Thursday as Wedbush downgraded the clinical-stage biotech citing its decision to pause Phase 1/2 dose-escalation trial for blood cancer therapy MGTA-117. The trial involving patients with relapsed/refractory acute myeloid leukemia (A...

Magenta Therapeitics ( NASDAQ: MGTA ) has halted a phase 1/2 trial of MGTA-117 for acute myeloid leukemia and myelodysplastic syndrome following the death of a patients that nay be related to the candidate. The participant experienced a Grade 5 Serious Adverse Event, respiratory failu...

CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and mye...

Magenta Therapeutics ( NASDAQ: MGTA ) has dropped 50% in Tuesday morning trading after it stopped dosing in a cohort of an acute myeloid leukemia candidate dose escalation trial due to toxicities . Two of the three participants in that cohort experienced dose-limiting tox...

– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities – – Plan to Dose Additional Participants in Cohort 3 per Clinical Trial Protocol – CAMBRIDGE, Mass., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock We’re starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! Moving stocks this morning are clinical trial data, earnings reports, business updates,...

Magenta Therapeutics ( NASDAQ: MGTA ) is up 37% in after-hours trading after posting phase 1/2 data on MGTA-117 for acute myeloid leukemia (AML) and myelodysplastic syndrome ( MDS ) that the company said demonstrates proof-of-concept. The candidate is an anti-CD117 an...

– MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory...